Abnormal mucociliary transport in allergic patients with antigen-induced bronchospasm

Role of slow reacting substance of anaphylaxis

T. Ahmed, D. W. Greenblatt, S. Birch, B. Marchette, Adam Wanner

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

We evaluated the possible role of slow reacting substance of anaphylaxis (SRS-A) in mediating mucociliary dysfunction in allergic asthma. In 6 asymptomatic nonsmokers with ragweed asthma, we measured specific airway conductance (SGaw) and tracheal mucous velocity (TMV) before and after bronchial challenge with ragweed extract, with or without pretreatment with 0.5% and 1% FPL-55712 (SRS-A antagonist). Mean baseline TMV was 8.9 mm/min (SD, 1.1). Placebo and FPL-55712 per se had no effect on TMV. With placebo pretreatment, the doses of ragweed extract that resulted in a decrease in SGaw by more than 35% from baseline, led to an immediate decrease in TMV to 74% of baseline (p<0.05), returning to baseline within 2 h. With 0.5% and 1% FPL-55712 pretreatment, doses of ragweed extract that resulted in a similar decrease in SGaw led to an increase in TMV to 130% and 126% of baseline (p<0.05), respectively, immediately after antigen challenge and returned to baseline 2 h postchallenge. Inhalation of 1% FPL-55712 immediately after antigen challenge prevented the decrease in TMV. These results indicated that (a) SRS-A liberated during airway anaphylaxis impairs mucous transport, and (b) the antigen-induced increase in TMV after pretreatment with an SRS-A antagonist may reflect a stimulatory effect of other chemical mediators of anaphylaxis.

Original languageEnglish
Pages (from-to)110-114
Number of pages5
JournalAmerican Review of Respiratory Disease
Volume124
Issue number2
StatePublished - Oct 26 1981
Externally publishedYes

Fingerprint

SRS-A
Ambrosia
Mucociliary Clearance
Bronchial Spasm
Antigens
Anaphylaxis
Asthma
Placebos
Inhalation
FPL 55712

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Abnormal mucociliary transport in allergic patients with antigen-induced bronchospasm : Role of slow reacting substance of anaphylaxis. / Ahmed, T.; Greenblatt, D. W.; Birch, S.; Marchette, B.; Wanner, Adam.

In: American Review of Respiratory Disease, Vol. 124, No. 2, 26.10.1981, p. 110-114.

Research output: Contribution to journalArticle

@article{3d3055425eac48deb37543744b10dec5,
title = "Abnormal mucociliary transport in allergic patients with antigen-induced bronchospasm: Role of slow reacting substance of anaphylaxis",
abstract = "We evaluated the possible role of slow reacting substance of anaphylaxis (SRS-A) in mediating mucociliary dysfunction in allergic asthma. In 6 asymptomatic nonsmokers with ragweed asthma, we measured specific airway conductance (SGaw) and tracheal mucous velocity (TMV) before and after bronchial challenge with ragweed extract, with or without pretreatment with 0.5{\%} and 1{\%} FPL-55712 (SRS-A antagonist). Mean baseline TMV was 8.9 mm/min (SD, 1.1). Placebo and FPL-55712 per se had no effect on TMV. With placebo pretreatment, the doses of ragweed extract that resulted in a decrease in SGaw by more than 35{\%} from baseline, led to an immediate decrease in TMV to 74{\%} of baseline (p<0.05), returning to baseline within 2 h. With 0.5{\%} and 1{\%} FPL-55712 pretreatment, doses of ragweed extract that resulted in a similar decrease in SGaw led to an increase in TMV to 130{\%} and 126{\%} of baseline (p<0.05), respectively, immediately after antigen challenge and returned to baseline 2 h postchallenge. Inhalation of 1{\%} FPL-55712 immediately after antigen challenge prevented the decrease in TMV. These results indicated that (a) SRS-A liberated during airway anaphylaxis impairs mucous transport, and (b) the antigen-induced increase in TMV after pretreatment with an SRS-A antagonist may reflect a stimulatory effect of other chemical mediators of anaphylaxis.",
author = "T. Ahmed and Greenblatt, {D. W.} and S. Birch and B. Marchette and Adam Wanner",
year = "1981",
month = "10",
day = "26",
language = "English",
volume = "124",
pages = "110--114",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - Abnormal mucociliary transport in allergic patients with antigen-induced bronchospasm

T2 - Role of slow reacting substance of anaphylaxis

AU - Ahmed, T.

AU - Greenblatt, D. W.

AU - Birch, S.

AU - Marchette, B.

AU - Wanner, Adam

PY - 1981/10/26

Y1 - 1981/10/26

N2 - We evaluated the possible role of slow reacting substance of anaphylaxis (SRS-A) in mediating mucociliary dysfunction in allergic asthma. In 6 asymptomatic nonsmokers with ragweed asthma, we measured specific airway conductance (SGaw) and tracheal mucous velocity (TMV) before and after bronchial challenge with ragweed extract, with or without pretreatment with 0.5% and 1% FPL-55712 (SRS-A antagonist). Mean baseline TMV was 8.9 mm/min (SD, 1.1). Placebo and FPL-55712 per se had no effect on TMV. With placebo pretreatment, the doses of ragweed extract that resulted in a decrease in SGaw by more than 35% from baseline, led to an immediate decrease in TMV to 74% of baseline (p<0.05), returning to baseline within 2 h. With 0.5% and 1% FPL-55712 pretreatment, doses of ragweed extract that resulted in a similar decrease in SGaw led to an increase in TMV to 130% and 126% of baseline (p<0.05), respectively, immediately after antigen challenge and returned to baseline 2 h postchallenge. Inhalation of 1% FPL-55712 immediately after antigen challenge prevented the decrease in TMV. These results indicated that (a) SRS-A liberated during airway anaphylaxis impairs mucous transport, and (b) the antigen-induced increase in TMV after pretreatment with an SRS-A antagonist may reflect a stimulatory effect of other chemical mediators of anaphylaxis.

AB - We evaluated the possible role of slow reacting substance of anaphylaxis (SRS-A) in mediating mucociliary dysfunction in allergic asthma. In 6 asymptomatic nonsmokers with ragweed asthma, we measured specific airway conductance (SGaw) and tracheal mucous velocity (TMV) before and after bronchial challenge with ragweed extract, with or without pretreatment with 0.5% and 1% FPL-55712 (SRS-A antagonist). Mean baseline TMV was 8.9 mm/min (SD, 1.1). Placebo and FPL-55712 per se had no effect on TMV. With placebo pretreatment, the doses of ragweed extract that resulted in a decrease in SGaw by more than 35% from baseline, led to an immediate decrease in TMV to 74% of baseline (p<0.05), returning to baseline within 2 h. With 0.5% and 1% FPL-55712 pretreatment, doses of ragweed extract that resulted in a similar decrease in SGaw led to an increase in TMV to 130% and 126% of baseline (p<0.05), respectively, immediately after antigen challenge and returned to baseline 2 h postchallenge. Inhalation of 1% FPL-55712 immediately after antigen challenge prevented the decrease in TMV. These results indicated that (a) SRS-A liberated during airway anaphylaxis impairs mucous transport, and (b) the antigen-induced increase in TMV after pretreatment with an SRS-A antagonist may reflect a stimulatory effect of other chemical mediators of anaphylaxis.

UR - http://www.scopus.com/inward/record.url?scp=0019455110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019455110&partnerID=8YFLogxK

M3 - Article

VL - 124

SP - 110

EP - 114

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -